Amphera B.V. is focused on advancing its innovative MesoPher cell therapy, which utilizes autologous dendritic cells to combat cancer, specifically targeting mesothelioma and pancreatic cancer. The therapy is distinguished by its incorporation of PheraLys, a proprietary allogeneic tumor cell lysate that provides a diverse array of Tumor Associated Antigens. This unique formulation aims to enhance the immune response against tumors, as evidenced by ongoing clinical studies that demonstrate promising results in improving recurrence-free survival rates in patients with resected pancreatic cancer.

The clinical efficacy of MesoPher has been highlighted in recent trials, including a phase II study that reported a significant increase in the two-year recurrence-free survival rate for patients who had undergone standard chemotherapy. The therapy was well-tolerated, with only low-grade side effects, and showed a notable overall survival rate. The positive outcomes from these trials have garnered recognition from regulatory bodies, leading to Orphan Designation from both the FDA and EMA, which underscores the potential of MesoPher to provide significant benefits in treating pancreatic cancer.

Netherlands

Amphera is a late-stage biotechnology company developing cell therapies to treat cancer. MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.

Amphera

Company Details